Robert Cartwright, MD
Allergy & Immunology · Columbus, GANPI 1326129230
Payments from drug & device makers
Across 889 payments — averaging $762.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$152K
- Sanofi US Services Inc.$143K
- AstraZeneca$102K
- Pfizer$95K
- Regeneron$66K
- Astrazeneca UK Limited$60K
- plus $60K from 30 others
What the payments were for
- Consulting fees$3,3002%
- Speaking & faculty fees$147,95088%
- Travel & lodging$3,9792%
- Food & beverage$13,6428%
- Education$1480%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 207 | $151,939 |
| Sanofi US Services Inc. | 55 | $142,843 |
| AstraZeneca | 133 | $102,449 |
| Pfizer | 54 | $95,139 |
| Regeneron | 54 | $65,652 |
| Astrazeneca UK Limited | 6 | $59,994 |
| Alk-abello, Inc | 91 | $44,586 |
| Optinose US, Inc. | 18 | $4,460 |
| Novartis | 28 | $3,396 |
| Sanofi | 41 | $2,416 |
| Regeneron Healthcare Solutions, Inc. | 49 | $1,326 |
| Biocryst US Sales Co., LLC | 24 | $565 |
| Genentech USA, Inc. | 22 | $553 |
| Takeda Pharmaceuticals U.S.A., Inc. | 18 | $511 |
| CSL Behring | 15 | $347 |
| AbbVie | 13 | $339 |
| Amgen(2 entities) | 12 | $255 |
| Kaleo, Inc. | 10 | $189 |
| Incyte Corporation | 3 | $127 |
| Grifols USA, LLC | 5 | $110 |
| Lilly USA, LLC | 4 | $106 |
| Teva Pharmaceuticals USA, Inc. | 6 | $94 |
| Shire North American Group Inc | 4 | $77 |
| Aimmune Therapeutics, Inc. | 3 | $68 |
| Blueprint Medicines Corporation | 1 | $50 |
| ADMA Biomanufacturing LLC | 2 | $49 |
| Pharming Healthcare, Inc. | 2 | $41 |
| Cycle Pharmaceuticals Inc | 1 | $22 |
| Dermavant Sciences, Inc. | 1 | $20 |
| LEO Pharma Inc. | 1 | $18 |
| Merck | 1 | $18 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $18 |
| Galderma Laboratories, L.p. | 1 | $17 |
| Boehringer Ingelheim | 1 | $17 |
| Phadia US Inc. | 1 | $15 |
| Octapharma USA, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$97,906
- ANORO ELLIPTA$7,429
- Xhance$4,199
- ILARIS$2,883
- AIRSUPRA$255
- BREZTRI$250
- DUPIXENT$249
- NUCALA$242
- Rinvoq$118
- BREZTRI AEROSPHERE$114
- AREXVY$103
How this compares
$677,838 in reported general payments places this provider in the 90th percentile of 107 allergy & immunology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 155 | $134,634 |
| Dupixent SyringeDupilumab | 32 | $124,638 |
| XolairOmalizumab | 31 | $96,212 |
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 13 | $86,149 |
| XembifyImmune Globulin,gamma(Igg)klhw | 11 | $33,903 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 25 | $19,740 |
| Spiriva RespimatTiotropium Bromide | 27 | $14,453 |
| SymbicortBudesonide/Formoterol Fumarate | 33 | $10,654 |
| Epinephrine | 40 | $8,858 |
| Breo ElliptaFluticasone/Vilanterol | 15 | $7,279 |
| Advair HfaFluticasone Propion/Salmeterol | 17 | $5,225 |
| Ipratropium Bromide | 116 | $5,171 |
| Fluticasone Propionate | 284 | $4,860 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 27 | $4,303 |
| Qvar RedihalerBeclomethasone Dipropionate | 14 | $3,988 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta | $151,939 | $141,912170 claims |
| CSL BehringHizentra | $347 | $86,14913 claims |
| Grifols USA, LLCXembify | $110 | $33,90311 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $102,449 | $30,39458 claims |
| Boehringer IngelheimSpiriva Respimat | $17 | $14,45327 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $94 | $3,98814 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 107 allergy & immunology providers in Georgia.
Other allergy & immunology in Columbus
- Robert ChrzanowskiColumbus$941K
- Nathan SegallStockbridge$4.5M
- Tracy BridgesAlbany$1.5M
- Brad GoodmanSavannah$1.3M
- Michael BlaissRoswell$1.1M
- Stanley FinemanMarietta$855K
- Deborah BirxAtlanta$470K
- Jack EadesMacon$282K
- Bruce FinkelSavannah$277K
- Michael MaloneyGainesville$142K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.